The new facility, which represents the firm’s second location in the country, is expected to provide increased capacity and greater flexibility to meet the demands of clients both domestically and internationally
Officials celebrating the groundbreaking for the WuXi STA Middletown campus. (Credit: PR Newswire/ WuXi AppTec)
Pharmaceutical company WuXi STA has started construction on a new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware in the US.
The new facility, first announced in June last year, represents the firm’s second location in the country.
It is expected to provide increased capacity and greater flexibility to meet the demands of clients both domestically and internationally.
The advanced plant at the WuXi STA Middletown location, which is at 1091 Industrial Drive in the Middletown Business Center, will employ about 500 people full-time. It is expected to commence operations in 2025.
Phase I of the new campus will offer formulation development and clinical and commercial drug product manufacturing services.
It will also offer packaging, labelling, storage, and distribution services for clinical trial materials and commercial drug products for a variety of oral and injectable dosage forms.
WuXi STA provides a variety of services and complies with all legal requirements from its 12 locations in the US, Europe, and Asia.
The new facility will further improve the company’s global medication production capacity and capabilities, along with three existing drug product manufacturing locations in Couvet (Switzerland), Wuxi City (China), and Shanghai (China).
WuXi STA CEO and WuXi AppTec co-CEO Dr Minzhang Chen said: “I would like to thank our federal, state and local partners in Delaware for their continued support in the establishment of this site.
“WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain.
“With our integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.”